Stock Price Quote

SEQUENT SCIENTIFIC LTD.

NSE : SEQUENTBSE : 512529ISIN CODE : INE807F01027Industry : Pharmaceuticals & DrugsHouse : Sequent
BSE123.35-0.1 (-0.08 %)
PREV CLOSE ( ) 123.45
OPEN PRICE ( ) 124.15
BID PRICE (QTY) 123.30 (190)
OFFER PRICE (QTY) 123.55 (472)
VOLUME 37159
TODAY'S LOW / HIGH ( )122.95 124.80
52 WK LOW / HIGH ( )70.15 155.45
NSE123.500.15 (+0.12 %)
PREV CLOSE( ) 123.35
OPEN PRICE ( ) 124.35
BID PRICE (QTY) 123.35 (107)
OFFER PRICE (QTY) 123.50 (991)
VOLUME 245691
TODAY'S LOW / HIGH( ) 122.90 124.80
52 WK LOW / HIGH ( )70.6 155.5
BSE NSE
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 28-06 1985
Management Info
Kamal K Sharma - Chairman Rajaram Narayanan - Managing Director
Registered Office

Address 301, ' Dosti Pinnacle',3rd Floor, Plot No. E7,Road No. 22, Wagle Indl. Estate,
Thane,
Maharashtra-400604

Phone 022 4111 4777

Email investorrelations@sequent.in

Website www.sequent.in

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
 Listing : BSE, NSE

NEWS

18Apr Announcement under Regulation 30 (LOD
Allotment of Equity Shares under Sequent Scientific Limited Employee Sto..
04Apr Sequent Scientific informs about resig
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosur..
08Feb Sequent Scientific to sell plot locate
Sequent Scientific has executed Deed of assignment on February 08, 2024,..
13Nov Sequent Scientific informs about trans
Pursuant to Regulation 30(6) of the Securities and Exchange Board of Ind..
25Sep USFDA completes inspection at Sequent
The United States Food and Drug Administration (USFDA) has completed ins..
MORE

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit45.8-60.8000000000003
Gross Profit 60.9 -97.4600000000003
Operating Profit 92.8818.8199999999997
Net Sales 422.052226.85
MORE

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Procter&Gamble Healt (BSE)
peergroup  4765.15 (1.38%)
M.Cap ( in Cr)7846.94
Mankind Pharma (BSE)
peergroup  2400.80 (2.69%)
M.Cap ( in Cr)96311.48
Astrazeneca Pharma I (BSE)
peergroup  5273.05 (1.06%)
M.Cap ( in Cr)13099.50
Fredun Pharma (BSE)
peergroup  813.00 (6.25%)
M.Cap ( in Cr)376.67
Torrent Pharma (BSE)
peergroup  2630.00 (1.52%)
M.Cap ( in Cr)88554.25
MORE

Shareholding Pattern

PROMOTERS 52.79%
MUTUAL FUNDS/UTI 5.16%
NON-INSTITUTION 33.46%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%
MORE

About Sequent Scientific Ltd.

Sequent Scientific Ltd. was incorporated in the year 1985. Its today's share price is 123.35. Its current market capitalisation stands at Rs 3067.37 Cr. In the latest quarter, company has reported Gross Sales of Rs. 2251.81 Cr and Total Income of Rs.2509.7 Cr. The company's management includes Vedprakash Ragate, Phillip Trott, Hari Babu Bodepudi, Gregory John Andrews, Neeraj Bharadwaj, Fabian Kausche, Sharat Narasapur, Rajaram Narayanan, Kausalya Santhanam, Milind Sarwate, Kamal K Sharma.

It is listed on the BSE with a BSE Code of 512529 , NSE with an NSE Symbol of SEQUENT and ISIN of INE807F01027. It's Registered office is at 301, ' Dosti Pinnacle',3rd Floor, Plot No. E7,Road No. 22, Wagle Indl. EstateThane-400604, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Deloitte Haskins & Sells, Deloittee Haskins & Sells, SRBC & Co LLP

download beyond app
download beyond app
About Nirmal Bang About Nirmal Bang Awards & Accolades Careers at Nirmal Bang Contact Nirmal BangContact Dp Support Contact Trading Support
Product & Services Equity & Derivatives Trading Forex Trading Commodity Trading Institutional Broking Depository Services Loan Against Securities (LAS) Algo Trading
Equity Price Analysis Volume Analysis Index Analysis News Analysis Corporate Action India Market Other Market Share Market Holidays T+1 Settlement securities
Derivatives Updates Market Report Overview
IPO IPO Issues Performance News & Analysis
Commodities Market Movers News & Commentary MCX / NCDEX HolidaysMCX Data feed product and Charges
Portfolio Management Service (PMS) NBSPL - PMS Disclosure Nirmal Bang PMS - Investor Charter SCORES complaints – March 2024
Mutual Funds About Nirmal Bang Niveshalaya Why Associate with Nirmal Bang Mutual Fund Login Mutual Fund Register FAQs Mutual Fund Holidays SIP Calculator Mutual Funds Updates Mutual Funds Trends Mutual Fund Reports Mutual Fund Terms & Conditions Mutual Privacy Policy
NPS NPS Forms and Guidelines NPS-AML Policy
Nirmal Bang Research Technical Calls Equity Reports Commodity Reports Currency Research Institutional Research
Nirmal Bang Media Knowledge Center Blog Support Center Become A Partner Beyond Market Careers Sitemap Do's And Dont'sInvestor Complaint Data
Other Links Disclaimer Privacy Policy Terms Of Use Rules & Regulations Disclosures Risk Disclosure Grievances NPS Grievance Policy SEBI ScoresRMS Policy Inspection CSR Committee CSR Policy
CSR Activities
FY-2020-2021 FY-2021-2022 FY-2022-2023
Investor Charter
Linked content_Investor Charter for Depositories and DPs Investor Charter for Depositories and DPs Investor Charter for Stock Broker Investor Charter for Research Investor Complaints -RA Investor Complaints-NBEPL
Evoting
NSDL Evoting CDSL Evoting
Client Bank Account list Smartodr Login Investor Grievance Flow Registered AP’sSurrendered List of AP’sKYC Activation Process
Connect with Us
ATTENTION INVESTORS Depository IPO KYC Investor Guide
Inactive account treatmentNBSPL Policy of AMLNBEPL Policy of AMLNBSPL CSR Policy Physical Settlement Policy of Derivative Aadhar UpdationNirmalbang Privacy Policy V1.0 Documents in Vernacular Languages NBSPL PMS Disclosure Document
Nirmal Bang Securities Pvt. Ltd. : Member NSE – ID 09391, SEBI Registration No. NSE CM Segment INZ000202536, Member NSE – ID 09391, SEBI Registration No. NSE FO Segment INZ000202536, Member NSE – ID 09391, SEBI Registration No. NSE CDS Segment INZ000202536, Member NSE Commodity – ID 09391, SEBI Registration No. NSE COMMODITY Segment Exchange Registered Broker, Member MSEI – ID 1067, SEBI Registration No. MSEI CM Segment INZ000202536, Member MSEI – ID 1067, SEBI Registration No. MSEI FO Segment INZ000202536, Member MSEI – ID 1067, SEBI Registration No. MSEI CDS Segment INZ000202536, Member MCX – ID 56460, SEBI Registration No. MCX COMMODITY Segment INZ000202536, Member NCDEX – ID 1268, SEBI Registration No. NCDEX COMMODITY Segment INZ000202536, Member ICEX – ID 2073, SEBI Registration No. ICEX COMMODITY Segment INZ000202536, Member BSE – ID 0498, SEBI Registration No. BSE CM Segment INZ000202536, Member BSE – ID 0498, SEBI Registration No. BSE FO Segment INZ000202536, Member BSE – ID 0498, SEBI Registration No. BSE CDS Segment Exchange Registered Broker, Member BSE Commodity – ID 0498, SEBI Registration No. BSE COMMODITY Segment Exchange Registered Broker, SEBI Registration No. PMS INP000002981, SEBI Registration No. Research Analyst INP000002981, SEBI Registration No. DP Participants NSDL – CDSL IN-DP-CDSL 37-99,Member Comtrack Participant Id – ID 50274, Member NERL RP Id– ID R1447, Nirmal Bang Equities Private Limited Member BSE – ID 245, SEBI Registration No. BSE CM Segment INZ000186135, Member NSE – ID 13437, SEBI Registration No. BSE CM Segment INZ000186135, Member NSE – ID 13437, SEBI Registration No. NSE FO Segment INZ000186135, Member NSE Currency – ID 13437, SEBI Registration No. NSE CDS Segment INZ000186135, Member MSEI – ID 17780, SEBI Registration No. MSEI CM Segment INZ000186135, Member MSEI – ID 17780, SEBI Registration No. MSEI FO Segment INZ000186135, SEBI Registration No. Research Analyst Segment INH000001436, Nirmal Bang Commodities Private Limited Member MCX – ID 16590, SEBI Registration No. MCX COMMODITY Segment INZ000043630, Member NCDEX – ID 00362, SEBI Registration No. NCDEX COMMODITY Segment INZ000043630, Member ICEX – ID 1165, SEBI Registration No. ICEX COMMODITY Segment INZ000043630, Member NCDEX Spot Exchange – ID 10084,Comtrack Participant CPID -5040, Participant CDSL Commodity Repository Limited - 12013300
For any grievances, please get in touch on 022-62739390 and write a mail to Contact@nirmalbang.com with Subject line as Grievances/Complain.     |    

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by ●●● Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

AppleApp Store GooglePlay Store
AppleApp StoreGooglePlay Store
Support
Videos
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.